Xcout Intel
Alopexx, Inc.
Alopexx, Inc. is a U.S. biotechnology company developing broad-spectrum anti-infective vaccines and antibody-based therapies. Its programs target PNAG, a surface polysaccharide found on many bacterial and fungal pathogens, for potential treatment or prevention of serious infections.
Subscribe to see Alopexx, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Alopexx, Inc. at a glance
Alopexx, Inc. is a biotechnology company headquartered in United States. Its most recent funding round closed in September 2024. Xcout tracks 6 named people at Alopexx, Inc., including Daniel R. Vlock (Co-Founder, Chief Executive Officer and Chairman of the Board Designee).
Alopexx, Inc. leadership
- Daniel R. VlockCo-Founder, Chief Executive Officer and Chairman of the Board Designee
- Ann MacDougallIndependent Director Designee
- Gail H. CassellIndependent Director Designee
- Peter J. WerthDirector Designee
- Richard CohenIndependent Director Designee
- William W. ChinSenior Strategic Advisor, Director Designee
Alopexx, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | Undisclosed | 1 named | |
| Strategic | Undisclosed | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Alopexx, Inc. competitors
A few of Alopexx, Inc.'s closest competitors — see the full list of competitors and alternatives →
C3J Therapeutics, Inc. is a clinical-stage biotechnology company based in Los Angeles, California, focused on improving human health through the development of targeted antimicrobials.
Affinivax, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that pioneered a novel class of multiplex vaccine technologies.
Qpex Biopharma, Inc. is a biopharmaceutical company located in San Diego, California, specializing in infectious disease solutions as part of the Shionogi Group.
LimmaTech Biologics is a Swiss clinical-stage biotechnology company developing vaccines against bacterial infections, including drug-resistant pathogens. Its work includes conjugate vaccine candidates for Shigella and other diseases, serving pharmaceutical partners and ultimately patients at risk of serious bacterial infections.
Vaxdyn is a Seville-based biotechnology spin-off founded in 2011 that develops safe and effective multi-pathogen vaccines to prevent dangerous bacterial infections.
Omnix Medical is a biopharmaceutical company that develops novel antibiotic agents and antimicrobial peptides to treat infections caused by drug-resistant bacteria. The company focuses on creating first-in-its-class anti-infective therapeutics, such as its lead compound OMN6, to target life-threatening bacterial strains.
Get Alopexx, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Alopexx, Inc. in Xcout Intel
- 6 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- 5 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access